← ANALYST RATINGS · TIPRANKS
Enanta Pharmaceuticals (ENTA): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy0 Hold0 Sell
Ratings of 1 analysts in the last 3 months12-month forecast
Based on 1 price targets given in the last 3 months, the average target is $20.00, the highest $20.00, the lowest $20.00. The average is +80.2% from the last price of $11.10.
Analyst ratings 3
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.00 → $11.50−4.2% | Hold | +3.6% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $12.00 → $11.50−4.2% | Hold | +3.6% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $12.00 → $11.50−4.2% | Hold | +3.6% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $11.50 → $11.00−4.3% | Hold | −0.9% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $13.00 → $11.50−11.5% | Hold | +3.6% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.00 | Hold | +8.1% | Reiterated | 29.09.26on TipRanks 00:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $12.00 | Hold | +8.1% | Reiterated | 29.09.26on TipRanks 00:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $12.00 | Hold | +8.1% | Reiterated | 29.09.26on TipRanks 00:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $11.00 | Sell | −0.9% | Downgrade | 29.09.26on TipRanks 00:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $11.50 | Hold | +3.6% | Reiterated | 29.09.26on TipRanks 00:06 | — | |
| Brandon Folkes★★★★★★★★★★#10500 · hits 39% · avg −1.1% | H.C. Wainwright | $20.00 | Buy | +80.2% | Reiterated | 23.09.26on TipRanks Sep 22 05:45 | +2.6%next day −3.1% · 5 days +3.0% | ↗ |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $13.00 | Hold | +17.1% | Reiterated | 20.08.26on TipRanks 00:06 | — | |
| Unknown Analyst | Rodman & Renshaw | $20.00 | Buy | +80.2% | Initiated | 26.03.26on TipRanks Mar 27 06:40 | +4.6%next day −0.9% · 5 days +3.4% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $19.00 | Buy | +71.2% | Reiterated | 03.03.26on TipRanks 07:05 | +2.3%next day +4.0% · 5 days −4.8% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Enanta Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $20.00 at a price of $13.18 (+51.7%); now: $20.00 at $11.10 (+80.2%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 0 | 0 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q4 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.72 (from $-0.95 to $-0.55). Last quarter: $-0.67.
Sales
Next quarter’s sales estimate — $15M (from $14M to $16M). Last quarter: $14M.
Best top-analyst consensus in the sector · Healthcare
About Enanta Pharmaceuticals
- CEO: Jay R. Luly
- Employees: 120
- 4 Kingsbury Avenue, Watertown, MA, 02472, US
- www.enanta.com
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Data from the stock’s TipRanks forecast page, read 394 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗